Moderna

Q: Where is Moderna's headquarters located?

Moderna's corporate headquarters is situated in Cambridge, Massachusetts, a hub for biotechnology and pharmaceutical innovation. The company's state-of-the-art facilities are strategically placed in the vibrant life sciences ecosystem of the Boston metropolitan area.

Q: How long has Moderna been in operation?

Moderna was founded in 2010 and has been at the forefront of mRNA technology development for over a decade. The company's longevity and continuous research efforts have positioned it as a leader in the rapidly evolving field of messenger RNA-based therapeutics and vaccines.

13 cited products 259 protocol citations

Moderna is a pioneering biotechnology company that develops innovative mRNA-based therapeutics and vaccines.
Their research products, featured in numerous scientific protocols and publications, cover a diverse range of applications, including vaccine development, gene therapies, and biologic production.
Researchers can explore Moderna's latest products, track citation trends, and access valuable insights to support their own projects through the PubCompare.ai platform.
Moderna's cutting-edge technologies and extensive research pipeline continue to advance the field of mRNA-based medicine, providing scientists with powerful tools to drive scientific progress.

13 products from Moderna

Mrna 1273 by Moderna

Cited in 145 protocols

Sourced in United States, United Kingdom

MRNA-1273 is an mRNA-based vaccine candidate developed by Moderna. It is designed to encode the prefusion stabilized full-length spike protein of SARS-CoV-2. The core function of MRNA-1273 is to generate an immune response against the SARS-CoV-2 virus.

Spikevax by Moderna

Cited in 53 protocols

Sourced in United States, Germany

Spikevax is a COVID-19 vaccine developed by Moderna. It is a mRNA-based vaccine that encodes the SARS-CoV-2 spike protein.

Bnt162b2 by Moderna

Cited in 18 protocols

Sourced in United States

BNT162b2 is a messenger RNA (mRNA) vaccine candidate developed by Moderna. It is designed to induce an immune response against the SARS-CoV-2 virus, which causes COVID-19.

Mrna 1273 vaccine by Moderna

Cited in 17 protocols

Sourced in United States

MRNA-1273 is a vaccine candidate developed by Moderna. It is an mRNA-based vaccine that encodes the S-protein of SARS-CoV-2. The vaccine is designed to induce an immune response against the SARS-CoV-2 virus.

Comirnaty by Moderna

Cited in 7 protocols

Sourced in United States

Comirnaty is a mRNA-based vaccine product developed by Moderna. It is designed to induce an immune response against the SARS-CoV-2 virus, the causative agent of COVID-19. The core function of Comirnaty is to deliver mRNA encoding the SARS-CoV-2 spike protein to host cells, which then produce the spike protein and elicit an immune response.

Arnm 1273 by Moderna

Cited in 3 protocols

Sourced in United States

ARNm-1273 is a laboratory equipment product developed by Moderna. It is designed to assist in the production and analysis of mRNA-based therapeutics. The core function of ARNm-1273 is to facilitate the manufacturing and evaluation of mRNA-based vaccine candidates. Further details on its intended use or application are not available.

Cx 024414 by Moderna

Cited in 3 protocols

CX-024414 is a laboratory instrument designed for the detection and analysis of various biological samples. It utilizes advanced technologies to perform a range of analytical functions. The specific details and intended use of this product are not available for disclosure at this time.

Potassium chloride (kcl) by Moderna

Cited in 3 protocols

Sourced in Brazil

Potassium chloride is a chemical compound that is commonly used in laboratory settings. It is a white, crystalline powder that is soluble in water. Potassium chloride is an inorganic salt that provides a source of potassium and chloride ions.

Ad26 cov2 s by Moderna

Cited in 2 protocols

Ad26.COV2.S is a recombinant, replication-incompetent adenovirus type 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein. The product is designed to trigger an immune response against the SARS-CoV-2 virus.

Mrna 1273 spikevax by Moderna

Cited in 2 protocols

MRNA-1273/Spikevax is a vaccine product developed by Moderna. It is a messenger RNA (mRNA) vaccine that provides instructions for human cells to produce a harmless piece of the SARS-CoV-2 spike protein, which then triggers an immune response. The core function of this product is to generate an immune response against the SARS-CoV-2 virus.

Company FAQ

Where is Moderna's headquarters located?

How long has Moderna been in operation?

What types of equipment and research fields does Moderna typically work in?

As a pioneering mRNA company, Moderna's research and development focuses on advancing mRNA technology across a wide range of applications, including infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. The company leverages cutting-edge equipment and facilities to conduct both fundamental and translational research, driving innovation in the mRNA field.

Can PubCompare.ai help researchers working with Moderna products?

Absolutely! PubCompare.ai is a powerful tool that can assist researchers working with Moderna products by helping them locate relevant protocols and studies. By streamlining the search process and providing easy access to comparable information, PubCompare.ai can improve reproducibility, reduce common mistakes, and minimize inherent wastage in research involving Moderna's technologies and products.

Did you know that Moderna's name is a combination of the words 'modify' and 'RNA'?

You're right, that's a fun fact about Moderna! The company's name is a clever portmanteau of the words 'modify' and 'RNA', reflecting its core mission to leverage mRNA technology to modify and transform the way we approach medicine and healthcare. This unique name serves as a constant reminder of Moderna's innovative spirit and commitment to pushing the boundaries of scientific discovery.

Is this your company ?

Claim your company profile and access business tools

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!